{"id":522420,"date":"2021-08-03T16:10:08","date_gmt":"2021-08-03T20:10:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/"},"modified":"2021-08-03T16:10:08","modified_gmt":"2021-08-03T20:10:08","slug":"zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/","title":{"rendered":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">EMERYVILLE, Calif., Aug.  03, 2021  (GLOBE NEWSWIRE) &#8212; Zogenix\u00a0(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that\u00a0Stephen\u00a0J. Farr, Ph.D., President and Chief Executive Officer, and\u00a0Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on\u00a0Tuesday, August 10, 2021, at the\u00a0BofA SMID Cap 2H21 Ideas Conference.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: bottom\">\n            <strong>Zogenix Fireside Chat Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:9%;width:9%;min-width:9%;vertical-align: bottom\">Date:<\/td>\n<td style=\"max-width:91%;width:91%;min-width:91%;vertical-align: bottom\">Tuesday, August 10, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Time:<\/td>\n<td style=\"vertical-align: bottom\">10:30 AM Eastern Time<\/td>\n<\/tr>\n<\/table>\n<p>The fireside chat will be webcast live and archived for 90 days on\u00a0Zogenix&#8217;s\u00a0Investor Relations website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FAzxKlayzDkIKtpiHCW_YG6yuielCHG4cMRPuekW_XRwXDZKCM1OPX85SkiNETJrcT-gJPznX3RrvLFOov9btoflF2isaj91xBFqQTldRxKBEvVU1ntSlaXi4wIJZHDS\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/zogenixinc.gcs-web.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>About Zogenix<\/strong><br \/>\n        <br \/>Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company\u2019s first rare disease therapy, FINTEPLA<sup>\u00ae<\/sup> (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.<\/p>\n<p>\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p>\n        <u>Zogenix<\/u><br \/>\n        <br \/>Melinda Baker<br \/>Senior Director, Corporate Communications<br \/>+1 (510) 788-8732 |\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-blAbsP5GyKJfay0Qrx2lXxqzMcvItHkualcJgfuCgniO4iaz6McY5FBxBwdI75P0FWv9dFErrm3q7jMbAjc3oi3JmLSt6l7SuKUHAdfvSE=\" rel=\"nofollow noopener\" target=\"_blank\">corpcomms@zogenix.com<\/a>\u00a0<\/p>\n<p>\n        <u>Investors<\/u><br \/>\n        <br \/>Brian Ritchie\u00a0<br \/>Managing Director,\u202fLifeSci Advisors LLC<br \/>+1 (212) 915-2578 |\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vORiRREcdPLyU2qFxVNcC69pPVbuhYIyl2zEhtIHOA4m0zoFi9D83K2MUwWG21AE4pm4lo5IRClVEeaPaL38xUx05Jv-ow082_kSt1cZVWSNyZLJtzNbQ6P6ByZDUOLE\" rel=\"nofollow noopener\" target=\"_blank\">britchie@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>\n        <u>Media<\/u><br \/>\n        <br \/>Trish McCall<br \/>Porter Novelli<br \/>+1 (805) 390-3279<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SHHTzPCifr0QS72NXO3_QEudnvDM3j9_i46dR5XdttG4CQKCU82jWK0PYp2toFqSZuuJ5E6GvsSNXrCQiYOX0JqsBJ_18x3DCcki2zO1go3A_pFRfTyrFrJ1OUoT1hDx\" rel=\"nofollow noopener\" target=\"_blank\">trish.mcall@porternovelli.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6eda1258-d8ce-4ee5-b650-987a3432d833\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Zogenix\u00a0(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that\u00a0Stephen\u00a0J. Farr, Ph.D., President and Chief Executive Officer, and\u00a0Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on\u00a0Tuesday, August 10, 2021, at the\u00a0BofA SMID Cap 2H21 Ideas Conference. Zogenix Fireside Chat Details Date: Tuesday, August 10, 2021 \u00a0 \u00a0 Time: 10:30 AM Eastern Time The fireside chat will be webcast live and archived for 90 days on\u00a0Zogenix&#8217;s\u00a0Investor Relations website at\u00a0https:\/\/zogenixinc.gcs-web.com.\u00a0 About Zogenix Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company\u2019s first rare disease &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522420","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Zogenix\u00a0(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that\u00a0Stephen\u00a0J. Farr, Ph.D., President and Chief Executive Officer, and\u00a0Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on\u00a0Tuesday, August 10, 2021, at the\u00a0BofA SMID Cap 2H21 Ideas Conference. Zogenix Fireside Chat Details Date: Tuesday, August 10, 2021 \u00a0 \u00a0 Time: 10:30 AM Eastern Time The fireside chat will be webcast live and archived for 90 days on\u00a0Zogenix&#8217;s\u00a0Investor Relations website at\u00a0https:\/\/zogenixinc.gcs-web.com.\u00a0 About Zogenix Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company\u2019s first rare disease &hellip; Continue reading &quot;Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T20:10:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference\",\"datePublished\":\"2021-08-03T20:10:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/\",\"name\":\"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\",\"datePublished\":\"2021-08-03T20:10:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/","og_locale":"en_US","og_type":"article","og_title":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk","og_description":"EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Zogenix\u00a0(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that\u00a0Stephen\u00a0J. Farr, Ph.D., President and Chief Executive Officer, and\u00a0Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on\u00a0Tuesday, August 10, 2021, at the\u00a0BofA SMID Cap 2H21 Ideas Conference. Zogenix Fireside Chat Details Date: Tuesday, August 10, 2021 \u00a0 \u00a0 Time: 10:30 AM Eastern Time The fireside chat will be webcast live and archived for 90 days on\u00a0Zogenix&#8217;s\u00a0Investor Relations website at\u00a0https:\/\/zogenixinc.gcs-web.com.\u00a0 About Zogenix Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company\u2019s first rare disease &hellip; Continue reading \"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T20:10:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference","datePublished":"2021-08-03T20:10:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/","name":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==","datePublished":"2021-08-03T20:10:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjA3NiM0MzM4OTY0IzUwMDA2NzQ2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zogenix-to-participate-in-the-bofa-securities-smid-cap-2h21-ideas-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522420"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522420\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}